

PROJECT DETAILS

Project Title:

Predicting response to tumor-infiltrating lymphocyte treatment in melanoma

Project Summary: aims, significance, expected outcomes and potential research impact.

Adoptive cell therapy (ACT) with tumor-infiltrating lymphocytes (TIL) has demonstrated durable responses in patients with solid malignancies, particularly for cutaneous melanoma. Through collaboration with the Harry Perkins Institute of Medical Research and Centre for Tissue Therapy WA, our team will deliver a TIL ACT treatment called Perkileucel. This cell therapy will be manufactured in Therapeutic Goods Administration (TGA)-accredited laboratories in Perth, and a clinical trial will open at the end of 2024. The PhD project aims to evaluate biomarkers in blood and tumor tissue to identify predictors of response to TIL ACT and monitor the patient's response to treatment.

Preferred applicant skill set, describe the capabilities of the HDR applicant:

We are looking for a motivated applicant who aspires to make a difference to cancer patients through the application of translational research, with background knowledge of immunology and molecular biology. The following attributes are desirable:

- Experience in statistics and machine learning, and
- Excellent organisational, problem-solving and project management skills.

Internship opportunity:

Potentially, through iPREP Biodesign which is based on an application process.

Contact person for the project:

Name:	Elin Gray	Contact number:	+618 6304 2756
Email:	e.gray@ecu.edu.au		